INV 600
Alternative Names: INV-600Latest Information Update: 13 Mar 2024
At a glance
- Originator INVENT Pharmaceuticals
- Class Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Obesity
Most Recent Events
- 27 Feb 2024 Invent Pharmaceuticals has patent protection for small molecules, prior to February 2024 (Invent Pharmaceuticals website, February 2024)
- 27 Feb 2024 Investigation in Obesity in USA (PO), before February 2024 (INVENT Pharmaceuticals pipeline, February 2024)